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Abstract: Although the life expectancy of thalassemia patients has markedly improved over the last 
few decades, patients still suffer from many complications of this congenital disease. The presence 
of a high incidence of thromboembolic events, mainly in thalassemia
identification of a hypercoagulable state in these patients. In this review, the molecular and cellular 
mechanisms leading to hypercoagulability in thalassemia are highlighted, with a special focus on 
thalassemia  intermedia  being  the  group  with  the  highest  incidence  of  thrombotic  events  as 
compared  to  other  types  of  thalassemia.  Clinical  experience  and  available  clues  on  optimal
management are also discussed.
Introduction: The thalassemias, a group of inherited 
disorders  of  hemoglobin  synthesis,  are  the  most 
common monogenetic disease worldwide.
diverse  phenotypes  exist  within  the  thalassemia 
syndromes. At one end of the spectrum is thalassemia 
minor,  a  clinically  silent,  mildly  hypochromic  and 
microcytic  anemia.  At  the  other  end  is  thalassemia 
major  (TM)  which  refers  to  those  patients  whose 
clinical  course  is  characterized  by  profound  anemia, 
who are presented to medical attention in the first year 
of  life,  and  who  subsequently  require  regular  blood 
transfusions  for  survival.
2 The  term  thalassemia 
intermedia (TI) was first suggested to describe patients 
who had clinical manifestations that were too severe to 
be  termed  minor  yet  too  mild  to  be  termed  major, 
although there remains substantial overlap between the 
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Although the life expectancy of thalassemia patients has markedly improved over the last 
few decades, patients still suffer from many complications of this congenital disease. The presence 
of a high incidence of thromboembolic events, mainly in thalassemia intermedia, has led to the 
identification of a hypercoagulable state in these patients. In this review, the molecular and cellular 
mechanisms leading to hypercoagulability in thalassemia are highlighted, with a special focus on 
g  the  group  with  the  highest  incidence  of  thrombotic  events  as 
compared  to  other  types  of  thalassemia.  Clinical  experience  and  available  clues  on  optimal
The thalassemias, a group of inherited 
disorders  of  hemoglobin  synthesis,  are  the  most 
common monogenetic disease worldwide.
1 Extremely 
diverse  phenotypes  exist  within  the  thalassemia 
syndromes. At one end of the spectrum is thalassemia 
minor,  a  clinically  silent,  mildly  hypochromic  and 
t  the  other  end  is  thalassemia 
major  (TM)  which  refers  to  those  patients  whose 
clinical  course  is  characterized  by  profound  anemia, 
who are presented to medical attention in the first year 
of  life,  and  who  subsequently  require  regular  blood 
The  term  thalassemia 
intermedia (TI) was first suggested to describe patients 
who had clinical manifestations that were too severe to 
be  termed  minor  yet  too  mild  to  be  termed  major, 
erlap between the 
three conditions.
3 Our understanding of the molecular 
and  pathophysiological  mechanisms  underlying  the 
disease  process  in  patients  with  TI  has  substantially 
increased  over  the  past  decade.
highlight  the  pathophysiology  of  TI,  ineffective 
erythropoiesis,  chronic  anemia/hemolysis,  and  iron 
overload secondary to increased intestinal absorption.
However,  the  extreme  diversity  in  phenotypic 
expression  in  TI  patients  led  to  a  wide  variation 
observed  clinical  complications.
complications  of  TI  that  were  found  to  occur  at  a 
higher  rate  than  in  patient
thromboembolic  events  (TEE).
hypercoagulability in patients with thalassemia and its 
translation into clinical TEE, with special emphasis on 
TI patients.
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Although the life expectancy of thalassemia patients has markedly improved over the last 
few decades, patients still suffer from many complications of this congenital disease. The presence 
intermedia, has led to the 
identification of a hypercoagulable state in these patients. In this review, the molecular and cellular 
mechanisms leading to hypercoagulability in thalassemia are highlighted, with a special focus on 
g  the  group  with  the  highest  incidence  of  thrombotic  events  as 
compared  to  other  types  of  thalassemia.  Clinical  experience  and  available  clues  on  optimal
Our understanding of the molecular 
and  pathophysiological  mechanisms  underlying  the 
isease  process  in  patients  with  TI  has  substantially 
increased  over  the  past  decade.
4 Three  main  factors 
highlight  the  pathophysiology  of  TI,  ineffective 
erythropoiesis,  chronic  anemia/hemolysis,  and  iron 
overload secondary to increased intestinal absorption.
4
However,  the  extreme  diversity  in  phenotypic 
expression  in  TI  patients  led  to  a  wide  variation  in 
observed  clinical  complications.
5 Among  the  clinical 
complications  of  TI  that  were  found  to  occur  at  a 
higher  rate  than  in  patients  with  TM  are 
thromboembolic  events  (TEE).
6-7 We  herein  review 
hypercoagulability in patients with thalassemia and its 
translation into clinical TEE, with special emphasis on Mediterr J Hematol Infect Dis 2011; 3: Open Journal System
Pathophysiology: Hypercoagulability in patients with 
thalassemia has been attributed to several risk factors.
8
It is often a combination of these factors that leads to 
TEE. 
It is widely accepted that patients with thalassemia 
have  chronically  activated  platelets,  and  enhanced 
platelet  aggregation,
9 as  confirmed  by  the  increased 
expression of CD62P (P-selectin) and CD63, markers 
of  in  vivo  platelet  activation.
10-11 Platelets  in 
thalassemia  have  a  shorter  life  span,  particularly  in 
splenectomized  patients,  due  to  enhanced 
consumption.
12 It  has  also  been  shown  that 
splenectomized  TM and  non-splenectomized  TI 
patients  have  4  to  10  times  more  metabolites  of 
prostacyclin  (PGI2)  and  thromboxane  A2  (TXA2), 
both  markers  of  hemostatic  activity,  than  controls. 
However, no significant difference was found between 
TM and TI patients.
13 Thus, the higher  rate of TEE in 
patients with TI compared to TM cannot be explained 
by  abnormalities  in  platelet  function,  and  shifts  the 
attention  to the  pathogenic  role  of  red  blood  cells 
(RBCs) described hereafter. Splenectomy also leads to 
higher platelet count.
14-15
Furthermore,  the  oxidation  of  globin  subunits  in 
thalassemia  erythroid  cells leads  to  the  formation  of 
hemichromes,
2 which  precipitate,  instigating  heme 
disintegration  and  the  eventual release  of  toxic 
nontransferrin-bound  iron  species.
16 The  free  iron  in 
turn catalyzes the formation of reactive oxygen species, 
leading  to  oxidation  of  membrane  proteins  and 
formation  of  red-cell  “senescence”  antigens  like 
phosphatidylserine,
17 which  cause  the  thalassemic 
RBCs  to  become  rigid,  deformed,  and  to  aggregate, 
resulting  in  premature  cell  removal.
18 Thalassemic 
RBCs  with  negatively  charged  phospholipids  have 
been  shown  to  increase  thrombin  generation,
19-20 as 
evidenced by studies  using  the  protein annexin V,  a 
protein  with  high  affinity and  specificity for  anionic 
phospholipids.
20 Studies  have  also  shown  that 
splenectomized  patients  have  a  higher  number  of 
negatively  charged  RBCs  and  increased  thrombin 
generation.
21-22 Thalassemic RBCs also have enhanced 
cohesiveness  and  aggregability.  These  abnormalities 
have been reduced to normal range after introducing a 
blood transfusion.
23
TI patients were also found to have higher levels of 
procoagulant  microparticles  of  RBC,  leukocytic,  and 
endothelial origins compared to controls.
24
The presence of other peripheral blood elements in 
thalassemics  such  as  E-selectin  (ELAM-1), 
intercellular  adhesion  molecule-1  (ICAM-1),  von 
Willebrand  factor  (VWF) and  vascular  cell  adhesion 
molecule-1 (VCAM-1) indicates that endothelial injury 
or activation may be an aspect of the disease, aiding in 
the  recruitment  of  white  blood  cells  and  RBCS, 
promoting thrombosis.
25-26 Studies have demonstrated 
that RBCs from TM and TI patients show increased 
adhesion to cultured endothelial cells (EC).
27 Butthep 
et al. showed that in addition to the presence of EC 
expressing adhesion molecules and tissue factor in the 
circulation,  thalassemia  patients  also  have  decreased 
levels  of  Protein  C  and  Protein  S  compared  with 
normal.
28 Prothrombin fragment 1.2 (F1.2), a marker of 
thrombin generation, is elevated in patients with TI.
29
Prothrombotic mutations do not play a role in the 
hypercoagulability of thalassemia. Studies in Italy and 
Lebanon have revealed that the presence of factor V 
Leiden,  prothrombin,  and  methylene  tetrahydrofolate 
reductase mutations did  not contribute to  the  risk of 
TEE in patients with thalassemia.
30-31 The presence of 
cardiac,  hepatic,  or  endocrine  dysfunction  may  also 
contribute to the hypercoagulability in thalassemia.
8
Clinical Experience: Epidemiological data on TEE in 
thalassemia are scarce. Borgna-Pignatti et al. surveyed 
nine  Italian  pediatric  thalassemia  centers,  observing 
that 4% of the 683 patients with TM and 9.6% of the 
52 patients with TI had experienced a TEE.
6 The same 
group showed six years later that 1.1% of 720 patients 
with  TM  in  seven  Italian  centers  had  thrombosis
32. 
Cappellini et al. followed-up 83 patients with TI over 
10 years, 82 of whom were splenectomized, and found 
that  29%  (24/83)  experienced  a  venous  TEE.
22 One 
study directly implicated TEE as the cause of death in 
2.5% of transfusion-dependent thalassemia patients.
33
After  examining  data  from  8,860  patients  in  the 
Mediterranean area and Iran, Taher et al. observed that 
TEE  occurred  4.38  times  (95%CI  3.14  – 6.10,  P <
0.001)  more  frequently  in  TI  than  TM,  with  more 
venous events occurring in TI and more arterial events 
occurring in TM (Figure 1).
7 It was found that 14% of 
mortalities in the whole group were due to TEE
7. Age 
above 20 years, splenectomy, family history of TEE, 
and  previous  TEE  were  identified  as  the  main  risk 
factors  for  thrombosis  in  TI.  Furthermore,  the  study 
showed that 68% of TI patients that had a TEE had an 
average hemoglobin level of < 9 g/dl and only 33% 
were  receiving  regular  blood  transfusions,  whereas 
94%  were  splenectomized.
7 Moreover,  patients 
receiving aspirin therapy had a significantly lower rate 
of recurrent TEE.
7
The evidence for brain involvement in thalassemia 
dates back to 1972 where 20% of 138 TM patients in 
Greece  were  found  to  have  neurological  deficits 
compatible  with  transient  ischemic  attacks  (TIAs).
34
Further  evidence  of  TIAs  causing  neurological 
symptoms,  such  as  headaches,  hemiparesis,  and
seizures was shown in  2.2% of patients with TM in 
Italy.
6 Although overt stroke occurs more frequently inMediterr J Hematol Infect Dis 2011; 3: Open Journal System
Figure 1. Type of thromboembolic events in thalassemia intermedia (TI) vs. thalassemia major (TM).
7 DVT = deep vein thrombosis, PE = 
pulmonary embolism, PVT = portal vein thrombosis, STP = superficial thrombophlebitis.
TM than TI (28% vs. 9%, respectively),
7 it has been 
shown that as many as 37.5% of patients with TI have 
asymptomatic  brain  damage  on  magnetic  resonance 
imaging (MRI).
34 A more recent study determined that 
splenectomized  adults  with  TI  show  a  rate  of  silent 
white matter lesions as high as 60%.
35 The occurrence 
and  multiplicity  of  the  lesions  were  associated  with 
older age (mean age of 36.1 years for lesion positive-
patients vs. 26.1 years for lesion-negative patients) and 
transfusion naivety (83.3% of lesion-positive patients 
have  never  had  a  transfusion  vs.  25%  of  lesion-
negative patients).
35
In order to obtain much needed clinical data on the 
optimal management of patients with TI, the Overview 
on  Practices  in  Thalassemia  Intermedia  Management 
Aiming  for  Lowering  Complication  rates  Across  a 
Region  of  Endemicity  (OPTIMAL  CARE)  study 
evaluated  584 patients with TI at  six  comprehensive 
care centers (Lebanon, Italy, Iran, Egypt, United Arab 
Emirates,  and  Oman)  for  the  associations  between 
patient and disease characteristics, treatment received, 
and  the  rate  of  complications.
5 The  study  analyzed 
complications  against the  parameters  of age,  gender, 
serum  ferritin  level,  hemoglobin  level,  splenectomy, 
transfusion, hydroxyurea, and  iron  chelation  therapy. 
Thrombosis  was  the  5
th most  common  complication, 
affecting  14%  of  the  patient  population.  On 
multivariate analysis, splenectomy, age above 35 years, 
and a serum ferritin level ≥ 1000 µg/l were associated 
with  a  higher  risk  for  thrombosis.
5 Conversely,  a 
positive history of transfusion and a hemoglobin level 
≥ 9 g/dl were found to be protective against thrombosis 
(Table 1).
5 Another study further confirmed the higher 
occurrence of thrombosis with advancing age.
36
In  an  effort  to  further  understand  the  effect  of 
splenectomy  on  TEE,  a  sub-study of  the  OPTIMAL 
CARE examined the characteristics of splenectomized
patients with TI who develop TEE aiming to identify 
high-risk patients who deserve further consideration for 
preventive  strategies.
37 Splenectomized  patients  with 
documented TEE (Group I, n = 73) were age- and sex-
matched  with  splenectomized  patients  without  TEE 
(Group  II)  and  non-splenectomized  patients  without 
TEE  (Group  III).  The  study  determined  that 
splenectomized  TI  patients  who  experience  TEE  are 
characterized by high nucleated RBC (≥ 300 x 10
6/l) 
and platelet counts (≥ 500 x 10
9/l), are more likely to 
have evidence of pulmonary hypertension (PHT) and 
be transfusion naïve. As such, the authors suggest that 
splenectomized TI patients at risk of developing TEE 
may be identified early on by these laboratory markers, 
presence of PHT, and transfusion status.
37 The study 
further  examined  how  long  it  took  for  a  TEE  to 
develop following splenectomy and found the median 
time to thrombosis to be 8 years.
37 The delay indicates 
that  the  etiology  behind  TEE  in  splenectomized 
patients  with  TI  is  not  an  acute  complication,  but  a 
manifestation of a chronic underlying process, further 
emphasizing  the  need  for  a  long-term  treatment 
modality for prevention.
37
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Table 1. Predictors of thrombosis in the OPTIMAL CARE study.
5
Parameter Adjusted OR 95% CI P-value
Age > 35 2.59 1.39 – 4.87 0.003
Female 1.27 0.74 – 2.19 0.387 
Hemoglobin ≥ 9 g/dl 0.41 0.23 – 0.71 0.001
Ferritin ≥ 1000 µg/L 1.86 1.09 – 3.16 0.023
Splenectomy 6.59 3.09 – 14.05 < 0.001
Transfusion 0.28 0.16 – 0.48 < 0.001
Hydroxyurea 0.56 0.28 – 1.10 0.090
Iron chelation 0.97 0.56 – 1.68 0.912
Management: The reduction of procoagulant RBCs by 
transfusion has been suggested as a reason behind the 
lower  rate  of  TEE  in  transfused  vs.  non-transfused 
patients.
5,7,35,37 As  such,  transfusion  therapy  may  be 
worthwhile  to  prevent  the  occurrence  of TEE, 
especially in TI patients in whom current practice does 
not necessarily recommend transfusions. However, this 
needs to be prospectively evaluated.
Since splenectomy is a major contributor to TEE in 
patients  with  thalassemia,  reassessment  of  the 
procedure  and  appropriate  risk  benefit-evaluation  is 
called  for.  This  is  also  important  because  of  its 
correlation  with  other  complications  such  as 
osteoporosis,  PHT,  cholelithiasis,  hypothyroidism, 
diabetes mellitus, heart failure, increased susceptibility 
to infection, and leg ulcers in TI.
5
The literature lacks proper evidence on the role of 
antiplatelet or anticoagulant agents in the management 
of  thalassemia.
8 The  lower  recurrence  of TEE  in  TI 
patients who took aspirin after their first TEE, when 
compared to those  who did not,  suggests a potential 
role for aspirin.
7 Moreover, the association of higher 
platelet  counts  with  TEE  in  patients  with  TI  further 
suggests a role for aspirin in this patient population.
37
Fetal  hemoglobin  inducing  agents  like  decitabine 
and  hydroxycarbamide  were  also  shown  to  lower 
plasma  markers  of  thrombin  generation.
29
Hydroxycarbamide  may  modulate  hypercoagulability 
in several ways, it may reduce phospholipid expression 
on  the  surface  of  RBCs  and  platelets,  and  decrease 
RBC adhesion to thrombospondin, a thrombin sensitive 
protein.
29 It  may  also  decrease  leukocyte  count, 
particularly monocytes expressing transcription factor, 
in addition to being a nitric oxide donor.
38
It  is  recommended  that  each  patient  be  assessed 
individually  and  assigned  a  personalized  thrombotic 
risk  based  on  intrinsic  (thalassemia  type,  number  of 
circulating  RBCs,  etc)  and  extrinsic  factors 
(splenectomy, transfusion status, etc).
29 High nucleated 
RBC  and  platelet  counts,  evidence  of  PHT,  and 
transfusion naivety can be used as indicators of TEE 
for  splenectomized  patients  with  TI  and  could  be 
practical  in  the  clinical  setting.
37 Such  a  risk-
assessment  model  (RAM)  would  be  valuable  in 
identifying  high-risk  patients  and  targeting  them  for 
further testing. The RAM could serve as a guideline for 
preventative  treatment  and  significantly  decrease 
morbidity  and  mortality.
29 Other  diagnostic  tests  are 
being explored to  help identify patients at risk, with 
promising preliminary results.
39
Conclusions: The hypercoagulable state in thalassemia
is due to multiple elements, a combination of which is 
often the drive behind a clinical TEE. Splenectomy and 
transfusion  naivety  are  increasingly  highlighted  as 
important risk factors for TEE, especially in patients 
with TI. An individualized approach is recommended 
to  establish  an  optimal  strategy  for  preventing  the 
occurrence of this complication if thalassemia.
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